What's New at CBER Update

["U.S. Food & Drug Administration (FDA)" <fda@xxxxxxxxxxxxxxxxxxxxxxx>]

Title: What's New at CBER Update

Having trouble viewing this email? View it as a Web page.

What's New at CBER

 

You are subscribed to What's New at CBER for the U.S. Food & Drug Administration (FDA).

 

---

Today Congress passed the FDA Reauthorization Act (FDARA) of 2017. This new legislation reauthorizes the user fee programs necessary for the continued support of the agency’s pre-market evaluation of prescription drugs, medical devices, generic drugs, and biosimilar products. The timely reauthorization of these programs ensures continuity for our medical product review programs and is crucial to supporting our mission of protecting and promoting public health.

---

This page has been updated recently.

• Influenza Virus Vaccine for the 2017-2018 Season
  Updated: 8/3/2017

---

Center for Biologics Evaluation and Research

Follow CBER on Twitter @FDACBER

Contact us at 1-800-835-4709 or ocod@xxxxxxxxxxx

---

Privacy Policy: http://www.fda.gov/privacy

Subscriber Services:
Manage Preferences  |  Unsubscribe  |  Help with this service

Stay Connected to FDA:

---

This email was sent to list-fda@xxxxxxxxxxx using GovDelivery Communications Cloud on behalf of: U.S. Food & Drug Administration (FDA) · 10903 New Hampshire Ave · Silver Spring, MD 20993 · 1-888-INFO-FDA (1-888-463-6332)